tbuckley/cabot-search huggingface dataset:
The Cap-Translation Inhibitor 4EGI-1 Induces Apoptosis in Multiple Myeloma Through Noxa Induction and Synergizes with ABT-737
Authors: Géraldine Descamps, Patricia Gomez-Bougie, Didier Bouscary, Philippe Moreau, Régis Bataille, Catherine Pellat-Deceunynck, Martine Amiot
Journal: Blood (2011)
Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial
Authors: Tatsuya Atsumi, Yoshiya Tanaka, Kazuhiko Yamamoto, Tsutomu Takeuchi, Hisashi Yamanaka, Naoki Ishiguro, Katsumi Eguchi, Akira Watanabe, Hideki Origasa, Shinsuke Yasuda, Yuji Yamanishi, Yasuhiko Kita, Tsukasa Matsubara, Masahiro Iwamoto, Toshiharu Shoji, Osamu Togo, Toshiyuki Okada, Désirée van der Heijde, Nobuyuki Miyasaka, Takao Koike
Journal: Annals of the Rheumatic Diseases (2017)

Objectives To investigate the clinical impact of 1-year certolizumab pegol (CZP) therapy added to the first year of 2-year methotrexate (MTX) therapy, compared with 2-year therapy with MTX alone. Methods MTX-naïve patients with early rheumatoid arthritis (RA) with poor prognostic factors were eligible to enter Certolizumab-Optimal Prevention of joint damage for Early RA (C-OPERA), a multicentre, randomised, controlled study, which consisted of a 52-week double-blind (DB) period and subsequent 52-week post treatment (PT) period. Patients were randomised to optimised MTX+CZP (n=159) or optimised MTX+placebo (PBO; n=157). Following the DB period, patients entered the PT period, receiving MTX alone (CZP+MTX→MTX; n=108, PBO+MTX→MTX; n=71). Patients who flared could receive rescue treatment with open-label CZP. Results 34 CZP+MTX→MTX patients and 14 PBO+MTX→MTX patients discontinued during the PT period. From week 52 through week 104, significant inhibition of total modified total Sharp score progression was observed for CZP+MTX versus PBO+MTX (week 104: 84.2% vs 67.5% (p&lt;0.001)). Remission rates decreased after CZP discontinuation; however, higher rates were maintained through week 104 in CZP+MTX→MTX versus PBO+MTX→MTX (41.5% vs 29.3% (p=0.026), 34.6% vs 24.2% (p=0.049) and 41.5% vs 33.1% (p=0.132) at week 104 in SDAI, Boolean and DAS28(erythrocyte sedimentation rate) remission. CZP retreated patients due to flare (n=28) showed rapid clinical improvement. The incidence of overall adverse events was similar between groups. Conclusions In MTX-naïve patients with early RA with poor prognostic factors, an initial 1 year of add-on CZP to 2-year optimised MTX therapy brings radiographic and clinical benefit through 2 years, even after stopping CZP. Trial registration number NCT01451203 .
Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the European Group for Blood and Marrow Transplantation (EBMT).
Authors: Mohamad Mohty, Myriam Labopin, Jean-Michel Boiron, Niklas Theorin, Axel Fauser, Alessandro Rambaldi, Marc Boogaerts, Shimon Slavin, Ignazio Majolino, Didier Blaise, Vanderson Rocha
Journal: Blood (2005)
Mitochondria in the spotlight of aging and idiopathic pulmonary fibrosis
Authors: Ana L. Mora, Marta Bueno, Mauricio Rojas
Journal: Journal of Clinical Investigation (2017)

Idiopathic pulmonary fibrosis (IPF) is a chronic age-related lung disease with high mortality that is characterized by abnormal scarring of the lung parenchyma. There has been a recent attempt to define the age-associated changes predisposing individuals to develop IPF. Age-related perturbations that are increasingly found in epithelial cells and fibroblasts from IPF lungs compared with age-matched cells from normal lungs include defective autophagy, telomere attrition, altered proteostasis, and cell senescence. These divergent processes seem to converge in mitochondrial dysfunction and metabolic distress, which potentiate maladaptation to stress and susceptibility to age-related diseases such as IPF. Therapeutic approaches that target aging processes may be beneficial for halting the progression of disease and improving quality of life in IPF patients.
Abstract IA10: Precision chemoprevention with aspirin
Authors: Andrew T. Chan
Journal: Cancer Research (2017)

Abstract Remarkably consistent experimental and epidemiologic evidence demonstrates that aspirin is associated with a lower risk of colorectal cancer. Five placebo-controlled randomized controlled trials (RCTs) among individuals with a history of colorectal neoplasia showed that aspirin reduced the risk of recurrent adenomatous polyps, the precursors of the vast majority of cancers. Additionally, data from long-term follow-up of a RCT of aspirin among individuals with the Lynch hereditary colorectal cancer syndrome and a RCT of aspirin among women for primary prevention of cardiovascular disease and cancer demonstrated a lower risk of colorectal cancer associated with randomized aspirin treatment. As a reflection of the strength of the evidence, the U.S. Preventative Services Task Force (USPSTF) updated its primary prevention guidelines for aspirin in 2016. The USPSTF provided low-dose aspirin (81 mg/day) with a recommendation for chronic disease prophylaxis, including colorectal cancer prevention, among U.S. adults between ages 50-59, and possibly ages 60-69, with a greater than 10% ten-year risk of cardiovascular events. The new USPSTF recommendation represents a significant milestone for the field of preventive medicine. With the exception of tamoxifen for women at high-risk for breast cancer, this is the first medication recommended for cancer prevention by USPSTF guidelines. Despite this advance, broader recommendations for aspirin chemoprevention are limited by concerns about risk-benefit profile in view of the established association of aspirin with gastrointestinal bleeding. Thus, in concert with broader efforts to tailor prevention strategies, our group has led several studies into the mechanistic basis of aspirin's anti-cancer effect that has led to the development of intratumoral, germline, and circulating molecular correlates of outcomes. Such biomarkers can be exploited for risk stratification to more effectively target aspirin chemoprevention for those with more favorable risk-benefit profiles. In this presentation, we will review the evidence supporting a role for aspirin in the prevention and treatment of cancer, with a focus on novel strategies for molecular risk stratification. Citation Format: Andrew T. Chan. Precision chemoprevention with aspirin. [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes; 2016 Sep 17-20; Tampa, FL. Philadelphia (PA): AACR; Cancer Res 2017;77(3 Suppl):Abstract nr IA10.
Why we forget our dreams: Acetylcholine and norepinephrine in wakefulness and REM sleep
Authors: Andrea Becchetti, Alida Amadeo
Journal: Behavioral and Brain Sciences (2016)

The ascending fibers releasing norepinephrine and acetylcholine are highly active during wakefulness. In contrast, during rapid-eye-movement sleep, the neocortical tone is sustained mainly by acetylcholine. By comparing the different physiological features of the norepinephrine and acetylcholine systems in the light of the GANE (glutamate amplifies noradrenergic effects) model, we suggest how to interpret some functional differences between waking and rapid-eye-movement sleep.
Rapid Transport and Infusion of Hematopoietic Stem Cells Can Improve Outcome after Unrelated Donor Transplant.
Authors: Hillard M. Lazarus, Fangyu Kan, Sergey Tarima, Richard E. Champlin, Dennis Confer, Noelle Frey, Sergio Giralt, John E. Wagner, Mary M. Horowitz, Mary Eapen
Journal: Blood (2007)
Amelioration of Inflammation, Angiogenesis and CTGF Expression in an Arthritis Model by a TSP1-Derived Peptide Treatment.
Authors: Mario C. Rico, Julian L. Castaneda, Joanne M. Manns, Audrey B. Uknis, Fayez F. Safadi, Steven N. Popoff, Raul A. De La Cadena
Journal: Blood (2006)
Changes in Lipidome Composition during Brain Development in Humans, Chimpanzees, and Macaque Monkeys
Authors: Qian Li, Katarzyna Bozek, Chuan Xu, Yanan Guo, Jing Sun, Svante Pääbo, Chet C. Sherwood, Patrick R. Hof, John J. Ely, Yan Li, Lothar Willmitzer, Patrick Giavalisco, Philipp Khaitovich
Journal: Molecular Biology and Evolution (2017)

Lipids are essential components of the brain. Here, we conducted a comprehensive mass spectrometry-based analysis of lipidome composition in the prefrontal cortex of 40 humans, 40 chimpanzees, and 40 rhesus monkeys over postnatal development and adulthood. Of the 11,772 quantified lipid peaks, 7,589 change significantly along the lifespan. More than 60% of these changes occur prior to adulthood, with less than a quarter associated with myelination progression. Evolutionarily, 36% of the age-dependent lipids exhibit concentration profiles distinct to one of the three species; 488 (18%) of them were unique to humans. In both humans and chimpanzees, the greatest extent of species-specific differences occurs in early development. Human-specific lipidome differences, however, persist over most of the lifespan and reach their peak from 20 to 35 years of age, when compared with chimpanzee-specific ones.
CD117 Expression May Signify Enduring Proliferative Capacity of Amniotic Fluid-Derived Mesenchymal Stem Cells (MSC).
Authors: William K. Decker, Sufang Li, Dongxia Xing, Simon N. Robinson, Hong Yang, David Steiner, Paul J. Simmons, Martin Korbling, Kenneth J. Moise, Elizabeth J. Shpall
Journal: Blood (2007)
Human-Machine Collaboration in Cancer and Beyond
Authors: Ian M. Goldstein, Julie Lawrence, Adam S. Miner
Journal: JAMA Oncology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
RTRB-01UTILIZING THE GENOMICALLY ADJUSTED DOSE (GAD) TO IDENTIFY PATIENTS FOR ADJUVANT RADIATION DOSE ESCALATION IN GLIOBLASTOMA
Authors: Kamran Ahmed, Jacob Scott, Peter Johnstone, William Fulp, Javier Torres-Roca, Jimmy Caudell
Journal: Neuro-Oncology (2015)

BACKROUND: We have previously validated a multi-gene model of tumor radiosensitivity (RSI) in glioblastoma (GBM). We propose a model to personalize radiotherapy dose utilizing the linear quadratic model. METHODS: As RSI models the surviving fraction at 2 Gy (SF2), we are able to derive a patient specific alpha. These terms were used in the linear quadratic model to calculate a genomically adjusted dose (GAD) to model radiation effect. Clinical and array-based gene expression (Affymetrix HT Human Genome U133 Array Plate Set) level 2 data were downloaded from The Cancer Genome Atlas (TCGA). Inclusion criteria were receipt of radiation and temozolomide, expression data to determine RSI and MGMT level, and dose and fractionation. RESULTS: Median follow-up in this cohort was 11.4 months (range: 1.5-91 months). In patients with low MGMT expression (dichotomized at the median), age (p = 0.03) and ECOG performance status (p < 0.001) were found to be predictors of overall survival (OS) while GAD (p = 0.98) was not. When restricting the analysis to patients with high MGMT expression (n = 98), GAD was found to be a predictor of OS on univariate (p = 0.039) and multivariate analyses (p = 0.01) when assessed by quartiles. Kaplan-Meier (KM) rates of OS at 12 and 24 months were 77.1% and 32.1% in quartile 4 (GAD ≥ 17.6) compared to 52.4% and 17.5% in quartile 1 (GAD <8.5). We then modeled GAD for an escalated dose to 70 Gy, 80 Gy, and 90 Gy, and found an additional 25, 29, and 38 patients, respectively, in the MGMT high cohort who could achieve GAD ≥ 17.6 (quartile 4) with dose escalation. CONCLUSIONS: Modeling dose escalation with GAD, we identified a select population of patients with high MGMT expression whom we hypothesize may benefit from genomically guided increased dose in the adjuvant setting. This population may represent a cohort for future clinical trial enrollment.
Separation anxiety in panic disorder
Authors: N K Free, C N Winget, R M Whitman
Journal: American Journal of Psychiatry (1993)

A number of researchers have provided evidence that separation anxiety is an important antecedent or current affect in panic disorder. The objective of this pilot study was to test this hypothesis by comparing dreams, screen memories, and life situations of panic disorder patients with those of comparison patients.A recent dream with associations, screen memories with associations, and life situations at onset of symptoms were recorded verbatim during semistructured interviews with 20 patients with DSM-III-R panic disorder and 20 comparison subjects upon referral to a private outpatient practice. A judge blind to the diagnoses rated each of the dreams, screen memories, and life situations separately on each of the 10 Gottschalk-Gleser Content Analysis Scales, thereby measuring manifest and latent death, mutilation, separation, guilt, and shame anxiety and overt and covert hostility in each group.mean separation anxiety scores were significantly higher in both the dreams and screen memories of the panic disorder patients than in the comparison patients. Mean scores for covert hostility directed outward were significantly higher in the dreams of the panic disorder patients than in the comparison patients.The hypothesis that separation anxiety is a prevalent affective undercurrent in the dreams and screen memories of panic disorder patients was supported. Significantly higher covert hostility in the panic disorder patients' dreams may support Bowlby's observation that people with high separation anxiety tend to disavow their anger.
Phase 2 Study of Bortezomib Weekly or Twice Weekly Plus Rituximab in Patients with Follicular (FL) or Marginal Zone (MZL) Lymphoma: Final Results.
Authors: Sven De Vos, Shaker R. Dakhil, Peter McLaughlin, Mansoor N. Saleh, Robert Belt, Christopher Flowers, Charles Holladay, Mark Knapp, Anthony Boral, Tracy Zhang, Andre Goy
Journal: Blood (2006)
MRI investigation for groin pain in athletes: is radiological terminology clarifying or confusing?
Authors: Adam Weir, Philip Robinson, Brian Hogan, Andrew Franklyn-Miller
Journal: British Journal of Sports Medicine (2017)

Advances in the field of groin pain in athletes have long been hampered by the use of inconsistent and confusing nomenclature. This reflects a lack of clarity on whether pathology is clinically relevant and on differentiating between often multiple painful structures. In a systematic review of 72 studies, 33 different diagnostic terms were used1 to describe patient cohorts, often with similar clinical presentations.

A thorough patient and injury history and standardised complete physical examination remain the cornerstone for diagnosing athletes with groin pain. The Doha agreement defined four clinical entities (pubic, adductor, iliopsoas and inguinal-related groin) while also highlighting the hip and other possible causes of groin pain.2 This agreement aimed to simplify the terminology used to classify/diagnose athletes with groin pain and to provide a standardised approach to physical examination. This approach uses the patient's ‘known’ pain to identify the specific involved clinical entity. However, not all papers published since have adopted the terminology recommended in the Doha agreement.

There remains a lack of histopathological evidence to support the multiple pathological conditions implicated in groin pain. A single study examined …
Selective Depletion of CD25+ Host-Reactive Donor Lymphocytes from Allografts Preserves a CD25− CD4+foxp3+ Fraction of T Cells and Thereby Provides a Source for Efficient Reconstitution of Regulatory T Cells and Additional GVHD Control.
Authors: Stephan Mielke, Katayoun Rezvani, Scott R. Solomon, Bipin N. Savani, Raquel Nunes, Agnes Yong, John Schindler, Elizabeth J. Read, Ellen S. Vitetta, A. John Barrett
Journal: Blood (2006)
Trends in Beverage Consumption Among High School Students — United States, 2007–2015
Authors: Gabrielle Miller, Caitlin Merlo, Zewditu Demissie, Sarah Sliwa, Sohyun Park
Journal: MMWR Morbidity and Mortality Weekly Report (2017)

Beverages play an important role in the diets of adolescents because they help to maintain hydration and can provide important nutrients, such as calcium, vitamin D, and vitamin C (1). However, some beverages, such as sugar-sweetened beverages (SSBs) (e.g., soda or pop), provide calories with no beneficial nutrients. Beverage consumption patterns among American youth have changed over time; however, little is known about differences in consumption of various beverages by demographic characteristics such as grade in school, free/reduced price lunch eligibility, and race/ethnicity (2). CDC analyzed data from the 2007-2015 national Youth Risk Behavior Surveys (YRBS) to assess whether the prevalence of drinking non-diet soda or pop (soda), milk, and 100% fruit juice (juice) has significantly changed over time among U.S. high school students. During 2007-2015, daily soda consumption decreased significantly from 33.8% to 20.5%. During 2007-2011, daily milk and juice consumption did not significantly change, but during 2011-2015 daily milk and juice consumption decreased from 44.3% to 37.4% and from 27.2% to 21.6%, respectively. Although a decrease in daily soda consumption is a positive change, soda consumption remains high. Although there is not a specific recommendation for sugar-sweetened beverage consumption, the Dietary Guidelines for Americans 2015-2020 recommend that U.S. residents reduce sugar-sweetened beverage and sweet consumption to reduce intake of added sugars to less than 10% of calories per day. The Dietary Guidelines for Americans 2015-2020 recommend that persons choose beverages with no added sugars, such as water, in place of sugar-sweetened beverages, as one strategy for achieving the added sugars recommendation. Adolescents might need additional support in choosing more healthful beverages, such as low-fat milk, in place of SSBs.
GENO-28ANALYSIS OF NAB2-STAT6 GENE FUSION IN 17 CASES OF MENINGEAL SOLITARY FIBROUS TUMOR/HEMANGIOEPRICYTOMA
Authors: Sayaka Yuzawa, Hiroshi Nishihara, Lei Wang, Taichi Kimura, Masumi Tsuda, Tanino Michie, Shinya Tanaka
Journal: Neuro-Oncology (2015)
FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), and temozolomide (TMZ) for glioblastoma (GBM).
Authors: C. Grommes, S. Karimi, K. Beal, T. A. Chan, L. E. Abrey, P. H. Gutin, A. M. P. Omuro
Journal: Journal of Clinical Oncology (2011)

2048 Background: In GBM, VEGF inhibition decreases vascular permeability and MRI contrast enhancement (CE), which may or may not reflect meaningful anti-tumor activity. We sought to evaluate the relationships between different imaging modalities and anti-tumor activity in a prospective phase II trial of BEV, TMZ and HFSRT in GBM. Methods: Newly diagnosed GBM pts (N=40) received HFSRT with concomitant/ adjuvant BEV and TMZ. All pts underwent dynamic susceptibility contrast MR perfusion (DSC) at baseline, after HFSRT and every 2m. An FDG-PET scan was done at cycle 6. McDonald and RANO response criteria were applied. Results: DSC showed early/progressive decreases in relative cerebral blood volume (rCBV): baseline mean rCBV: 2.77; 6 weeks: 1.65 (p=0.014); 2m: 1.07 (p<0.001); 4m: 0.98 (p<0.001). Conversely, the extent of FLAIR hypersignal progressively increased (mean diameter product: 953, 1165, 1145, 1384 at 6 wks, 2m, 4m and 6m). Response rates per McDonald vs RANO were: complete response (27 vs 10%), partial (63 vs 63%), stable disease (3% vs 20%), progression (7 vs 7%). Because progressive FLAIR occurred within the RT port, time to radiographic progression per McDonald and RANO were identical: median 13m. Residual hypermetabolism seen at the 6m PET (N=6/31) predicted poor survival (p<0.001). Three pts with progressive FLAIR but not CE underwent re-resection; two had true PD and one had mainly radionecrosis. Conclusions: As treatment failure was mostly local, RANO criteria did not shorten time to progression compared to McDonald. DSC depicted early changes in rCBV linked to VEGF modulation, validating DSC as a reliable tool to evaluate anti-VEGF properties of new drugs in vivo. However, VEGF modulation was not predictive of durable anti-tumor activity. A positive PET at 6m predicted poor survival, indicating treatment failure even if other imaging modalities suggested otherwise. However, tumor progression may still be present despite negative PET and DSC, particularly in the setting of increasing non-enhancing FLAIR within the RT port. New imaging tools and improved response criteria are needed to guide management of these pts.
STAY HEALTHY: AN AUSTRALIAN INSTITUTE OF SPORT ILLNESS PREVENTION PROJECT
Authors: Michael Drew, Vlahovich Nicole, Hughes David, Appaneal Renee, Peterson Kirsten, Burke Louise, Lundy Bronwen, Toomey Mary, Watts David, Lovell Greg, Praet Stephan, Halson Shona, Colbey Candice, Manzanero Silvia, Welvaert Marijke, West Nic, Pyne David, Waddington Gordon
Journal: British Journal of Sports Medicine (2017)

Background Illnesses affect the ability of an athlete to perform. Few studies investigate risk factors in athletes across disciplines. Objective To investigate risk factors for illness in athletes preparing for the Olympic Games. Design Cross-sectional. Setting Australian athletes eligible for selection for the Olympic Games. Participants 317 athletes from 15 sports completed at least one component of the study (59% of athletes). To be eligible, athlete had to be available for selection for the Olympics. Assessment of Risk Factors Phase 1 (P1) was in the summer period of December 2015-January 2016 and Phase 2 (P2) involved the period in the autumn (late April-June 2016). Questionnaires were administered in an electronic system. Depression, Anxiety and Stress Questionnaire (DASS-21), Perceived Stress Scale (PSS), Dispositional Resilience Scale (DRS), Recovery-Stress Questionnaire (REST-Q-52 item), Low Energy in Females Questionnaire (LEAF-Q), a modified Personal and Household Hygiene questionnaire, Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index, and custom-made questionnaires on probiotic usage and travel were administered. Main Outcome Measurements A monthly sports incapacity defintion was used in P1. A symptom checklist, including sports incapacity, was utilized in P2 investigating Upper Respiratory Tract Symptoms (URTS), bodily aches, gastrointestinal, head, eye, fatigue or chest symptoms. Results Female athletes were at higher odds of respiratory illness (OR=2.8, 95% CI 1.3 to 6.0). The prevalence of a high LEAF-Q score (≥8) was 49 and 53% and was associated with illness (P1: Any illness OR 7.4, 95% CI 0.8–352; P2: URTS OR 3.8, 95% CI 1.3–11.6). High DASS-21 scores were associated with increased reports of illness in P1 (Depression, OR=8.4 95% CI 1.1–59). High PSQI scores increased the reports of illness (P2: URTS: PSQI≥5, OR=2.8 95% CI 1.2–6.9). Conclusions The results highlight that female athletes, particularly when exhibiting low energy availability, are at higher risk. Poor mental health and sleep quality were associated with illness.